smh.com.au
Cure8 news brief
Why This Matters
A positive pre‑IND response from the FDA makes it more likely this stem‑cell therapy will reach a formal Phase 2 trial, which could eventually expand treatment options for people with refractory or fistulising Crohn’s disease.
Who Should Pay Attention
Patients with treatment‑resistant or fistulising Crohn’s disease, clinicians treating complex IBD, researchers in cell‑therapy and IBD drug development, and caregivers following emerging therapies.
Study Snapshot
Story typeMainstream News
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
The FDA’s feedback answered six of seven questions favorably and agreed no further non‑clinical studies were needed; the remaining item is completion of a viral‑contamination testing protocol for manufacturing.
StemSmart is an off‑the‑shelf mesenchymal stem‑cell product derived from donor bone marrow and is intended for intravenous infusion in refractory and/or fistulising Crohn’s disease.
The company plans to begin the Phase 2 trial (Australia and US) pending regulatory, manufacturing and operational steps, and is transferring manufacturing to a commercial cell‑therapy partner.
The article summarizes company and regulator actions and prior small studies (including an 18‑patient study and a five‑person special access cohort) but does not report new trial results.
Keep In Mind
This article is a news report about a company announcement and FDA pre‑IND feedback; Phase 2 trials are still required to test safety and effectiveness. Prior studies cited were small and earlier‑phase, so their results should be seen as preliminary signals rather than definitive evidence.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationsmh.com.au
AuthorsPenny Taylor
Indexed viaBing News
Source typeWeb article
PublishedOct 12, 2026, 5:58 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Inside Biotech: NeuroScientific appoints Southern Star Research to advance Phase 2 Crohn’s disease trial
A new Phase 2 study of StemSmart™ could expand treatment options for patients with refractory or fistulising Crohn’s disease if later trials confirm safety and benefit. Appointment of a CRO is an early but important step...
NeuroScientific Biopharmaceuticals Reports Positive Results from StemSmart Crohn's Trial
This article reports an investigational stem cell therapy (StemSmart MSCs) showing safety and clinical responses in a small group of patients with fistulising Crohn’s disease — a serious complication that’s often hard to...
RedHill Biopharma announces plans to advance program for Crohn's disease
This reports a company moving a MAP-targeted antibiotic-like therapy (RHB-204, related to RHB-104) into a Phase 2 trial for Crohn’s disease with mucosal healing and MAP eradication as key endpoints—topics that could...